HC Wainwright Reiterates Buy Rating for MediWound (NASDAQ:MDWD)

MediWound (NASDAQ:MDWD)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They presently have a $36.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s target price would suggest a potential upside of 151.22% from the stock’s previous close.

Other equities analysts have also issued reports about the stock. Oppenheimer reiterated an “outperform” rating and issued a $32.00 price target on shares of MediWound in a research report on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MediWound in a research note on Tuesday, April 21st. Finally, Wall Street Zen cut shares of MediWound from a “hold” rating to a “strong sell” rating in a research report on Saturday, March 7th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $34.00.

MediWound Trading Down 14.1%

Shares of NASDAQ MDWD opened at $14.33 on Thursday. The firm has a 50 day moving average of $16.73 and a 200 day moving average of $17.48. The firm has a market capitalization of $184.17 million, a price-to-earnings ratio of -6.82 and a beta of 0.21. MediWound has a 12-month low of $14.14 and a 12-month high of $22.50.

MediWound (NASDAQ:MDWD) last announced its earnings results on Wednesday, May 27th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.42. The company had revenue of $1.48 million during the quarter, compared to analyst estimates of $3.37 million. MediWound had a negative net margin of 140.80% and a negative return on equity of 65.79%. During the same period in the previous year, the business posted ($0.07) earnings per share. Sell-side analysts predict that MediWound will post -2.75 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Quarry LP bought a new position in MediWound during the 4th quarter worth about $26,000. BNP Paribas Financial Markets raised its position in shares of MediWound by 90.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 723 shares during the last quarter. Russell Investments Group Ltd. raised its position in shares of MediWound by 69.1% in the 2nd quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 649 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of MediWound by 22.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock valued at $85,000 after purchasing an additional 999 shares during the last quarter. Finally, MetLife Investment Management LLC purchased a new position in shares of MediWound in the 4th quarter valued at approximately $109,000. 46.83% of the stock is currently owned by institutional investors.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.